Avanir Pharmaceuticals Announces Listing Of Additional NUEDEXTA Patent In FDA Orange Book

Avanir Pharmaceuticals, Inc. AVNR announced today that an additional patent covering Avanir's NUEDEXTA® (dextromethorphan HBr and quinidine sulfate) product has been listed in the U.S. Food and Drug Administration's (FDA) Orange Book. The Orange Book listing requires an Abbreviated New Drug Application (ANDA) applicant, seeking FDA approval for a generic version of NUEDEXTA prior to expiration of the patent, to notify Avanir of its ANDA filing before it can obtain FDA approval. Avanir Pharmaceuticals now has three patents listed in the FDA Orange Book: Patent number: RE38,115 which expires in 2016 Patent number: 8,227,484 which expires in 2023 Patent number: 7,659,282 which expires in 2026